{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:28:48Z","timestamp":1778797728172,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ashjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jash.2014.05.006","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T13:15:17Z","timestamp":1400159717000},"page":"578-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients"],"prefix":"10.1016","volume":"8","author":[{"given":"Hisato","family":"Takagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jash.2014.05.006_bib1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s00592-005-0176-0","article-title":"Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator","volume":"42","author":"Kurtz","year":"2005","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jash.2014.05.006_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.05.006_bib3","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2014.05.006_bib4","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/00004872-200412000-00003","article-title":"Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system","volume":"22","author":"Kurtz","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2014.05.006_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jash.2014.05.006_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1291\/hypres.27.457","article-title":"Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study","volume":"27","author":"Derosa","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-4-6","article-title":"Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome","volume":"4","author":"Vitale","year":"2005","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jash.2014.05.006_bib8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF03349207","article-title":"The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients","volume":"29","author":"Negro","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jash.2014.05.006_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2710.2007.00820.x","article-title":"Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone","volume":"32","author":"Derosa","year":"2007","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jash.2014.05.006_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1291\/hypres.31.601","article-title":"Telmisartan but not candesartan affects adiponectin expression in\u00a0vivo and in\u00a0vitro","volume":"31","author":"Yamada","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1291\/hypres.31.7","article-title":"Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension","volume":"31","author":"Nakayama","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib12","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.metabol.2008.05.019","article-title":"Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance","volume":"57","author":"Makita","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.jash.2014.05.006_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejim.2010.01.014","article-title":"Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus","volume":"21","author":"Ozaki","year":"2010","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jash.2014.05.006_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3132\/dvdr.2008.011","article-title":"Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus","volume":"5","author":"McGuire","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jash.2014.05.006_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1586\/14779072.6.3.289","article-title":"Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan","volume":"6","author":"Francischetti","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5 Suppl 1","key":"10.1016\/j.jash.2014.05.006_bib16","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.amjmed.2006.01.011","article-title":"New treatment strategies for patients with hypertension and insulin resistance","volume":"119","author":"Kurtz","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jash.2014.05.006_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1262-3636(07)70146-5","article-title":"Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials","volume":"30","author":"Scheen","year":"2004","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jash.2014.05.006_bib19","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","article-title":"Chapter 16: special topics in statistics","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jash.2014.05.006_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jash.2014.05.006_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.jash.2014.05.006_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2014.05.006_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1479164112444640","article-title":"The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)","volume":"10","author":"Murakami","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jash.2014.05.006_bib24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12325-011-0040-2","article-title":"Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE)","volume":"28","author":"Mori","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.jash.2014.05.006_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1291\/hypres.30.49","article-title":"Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome","volume":"30","author":"Bahadir","year":"2007","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/HYPERTENSIONAHA.111.173542","article-title":"High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-\u03b3 target genes in patients with the metabolic syndrome","volume":"58","author":"B\u00e4hr","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.05.006_bib27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.metabol.2006.04.013","article-title":"Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension","volume":"55","author":"Benndorf","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.jash.2014.05.006_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-2008-1081211","article-title":"Interactions of glucose metabolism and chronic heart failure","volume":"117","author":"Clodi","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.jash.2014.05.006_bib29","first-page":"275","article-title":"Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients","volume":"25","author":"de Luis","year":"2010","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.jash.2014.05.006_bib30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(04)80049-3","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jash.2014.05.006_bib31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1291\/hypres.29.849","article-title":"Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha","volume":"29","author":"Derosa","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib32","doi-asserted-by":"crossref","first-page":"587140","DOI":"10.1155\/2013\/587140","article-title":"Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: fatty liver protection trial by telmisartan or losartan study (FANTASY)","volume":"2013","author":"Hirata","year":"2013","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.jash.2014.05.006_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1055\/s-0029-1237359","article-title":"Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients","volume":"41","author":"Fogari","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jash.2014.05.006_bib34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3748\/wjg.15.942","article-title":"Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis","volume":"15","author":"Georgescu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jash.2014.05.006_bib35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1291\/hypres.31.615","article-title":"Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy","volume":"31","author":"Hinoi","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib36","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1136\/hrt.2011.225193","article-title":"Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients","volume":"97","author":"Hong","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jash.2014.05.006_bib37","first-page":"1017","article-title":"Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity","volume":"32","author":"Huang","year":"2011","journal-title":"Saudi Med J"},{"key":"10.1016\/j.jash.2014.05.006_bib38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2169\/internalmedicine.46.7173","article-title":"Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome","volume":"46","author":"Ichikawa","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.jash.2014.05.006_bib39","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1097\/HJH.0b013e328355860e","article-title":"Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome","volume":"30","author":"Kishi","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2014.05.006_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diabres.2011.05.039","article-title":"The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance","volume":"94","author":"Lan","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jash.2014.05.006_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1536\/ihj.50.85","article-title":"Comparison of therapies between fixed-dose telmisartan\/hydrochlorothiazide and losartan\/hydrochlorothiazide in patients with mild to moderate hypertension","volume":"50","author":"Minami","year":"2009","journal-title":"Int Heart J"},{"key":"10.1016\/j.jash.2014.05.006_bib42","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12325-012-0032-x","article-title":"Telmisartan at 80 mg\/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients","volume":"29","author":"Mori","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.jash.2014.05.006_bib43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3317\/jraas.2006.045","article-title":"The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients","volume":"7","author":"Negro","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jash.2014.05.006_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijcard.2008.10.048","article-title":"Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance","volume":"139","author":"Perl","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2010.03.018","article-title":"Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study","volume":"32","author":"Rizos","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jash.2014.05.006_bib46","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1097\/HJH.0b013e328312677e","article-title":"Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives","volume":"26","author":"Sanchez","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2014.05.006_bib47","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.clinthera.2009.10.010","article-title":"Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease","volume":"31","author":"Satoh","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.jash.2014.05.006_bib48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/HJH.0b013e3280287a83","article-title":"Effects of telmisartan on fat distribution in individuals with the metabolic syndrome","volume":"25","author":"Shimabukuro","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2014.05.006_bib49","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/hr.2011.114","article-title":"Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients","volume":"34","author":"Hasegawa","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib50","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.amjhyper.2007.07.013","article-title":"Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels","volume":"20","author":"Tomiyama","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2014.05.006_bib51","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2169\/internalmedicine.49.3189","article-title":"Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients","volume":"49","author":"Watanabe","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.jash.2014.05.006_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.amjhyper.2006.12.008","article-title":"The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients","volume":"20","author":"Yano","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2014.05.006_bib53","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.05.006_bib54","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.05.006_bib55","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/endo.143.3.8662","article-title":"Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization","volume":"143","author":"Combs","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jash.2014.05.006_bib56","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.2337\/diabetes.50.9.2094","article-title":"PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein","volume":"50","author":"Maeda","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2014.05.006_bib57","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.3945\/ajcn.2009.28449C","article-title":"Adiponectin in insulin resistance: lessons from translational research","volume":"91","author":"Ziemke","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jash.2014.05.006_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2009.976","article-title":"Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"302","author":"Li","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.05.006_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2337\/diabetes.54.2.534","article-title":"Adiponectin and future coronary heart disease events among men with type 2 diabetes","volume":"54","author":"Schulze","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2014.05.006_bib60","doi-asserted-by":"crossref","first-page":"45021","DOI":"10.1074\/jbc.M307878200","article-title":"Adiponectin stimulates production of nitric oxide in vascular endothelial cells","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jash.2014.05.006_bib61","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1161\/01.CIR.0000018622.84402.FF","article-title":"Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell","volume":"105","author":"Arita","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2014.05.006_bib62","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.amjcard.2007.06.068","article-title":"Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients","volume":"100","author":"Hong","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib63","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ijcard.2011.11.071","article-title":"Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials","volume":"155","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib64","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00041433-200312000-00003","article-title":"Obesity, adiponectin and vascular inflammatory disease","volume":"14","author":"Ouchi","year":"2003","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jash.2014.05.006_bib65","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/hh2101.099270","article-title":"Novel clinical markers of vascular wall inflammation","volume":"89","author":"Blake","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.jash.2014.05.006_bib66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jash.2014.05.006_bib67","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1463-1326.2007.00755.x","article-title":"The effect of thiazolidinediones on adiponectin serum level: a meta-analysis","volume":"10","author":"Riera-Guardia","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jash.2014.05.006_bib68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR-gamma: adipogenic regulator and thiazolidinedione receptor","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2014.05.006_bib69","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/hr.2012.196","article-title":"Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials","volume":"36","author":"Takagi","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib70","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.ijcard.2012.11.086","article-title":"Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: a meta-analysis of head-to-head randomized trials","volume":"167","author":"Takagi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib71","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/hr.2012.233","article-title":"A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction","volume":"36","author":"Takagi","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib72","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/hr.2013.78","article-title":"A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure","volume":"36","author":"Takagi","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.05.006_bib73","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1016\/j.ijcard.2012.11.081","article-title":"A meta-analysis of randomized head-to-head trials of telmisartan versus other angiotensin II receptor blocker in combination with hydrochlorothiazide for reduction of blood pressure","volume":"167","author":"Takagi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib74","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1751-7176.2010.00287.x","article-title":"A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension","volume":"12","author":"Zheng","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2014.05.006_bib75","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/jhh.2008.132","article-title":"Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials","volume":"23","author":"Zou","year":"2009","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2014.05.006_bib76","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2012.01.104","article-title":"Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials","volume":"156","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijcard.2012.02.008","article-title":"Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials","volume":"157","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib78","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijcard.2012.09.044","article-title":"Blood pressure-independent effects of telmisartan on regression of left ventricular mass: a meta-analysis and meta-regression of randomized controlled trials","volume":"165","author":"Takagi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.05.006_bib79","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ijcard.2012.04.058","article-title":"Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials","volume":"167","author":"Takagi","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114005579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114005579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T09:57:52Z","timestamp":1565431072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171114005579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1933171114005579"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2014.05.006","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2014.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}